News & Insights

Stay up to date on PsychoGenics’ latest research, press releases, and industry developments in preclinical drug discovery. Combine our expertise with yours to spark the translational power of your next CNS breakthrough.

POSTER

Functional, Sensorimotor, and Cognitive Outcomes Following Unilateral MCAO in Rats

June 24, 2026
Read More
POSTER

Behavioral and pharmacological characterization of the isosorbide dinitrate model of headache in male and female rats

June 15, 2026
Read More
INDUSTRY NEWS

The CNS Drug Development Drum Beat is Getting Louder

August 5, 2022
Read More
PRESS RELEASES

PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities

June 29, 2022
Read More
INDUSTRY NEWS

GBR Connect Series – Interview with Emer Leahy, PsychoGenics

March 15, 2022
Read More
PRESS RELEASES

PsychoGenics’ High Data Security Standards Are Certified by The NIH

January 25, 2022
Read More
PRESS RELEASES

PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development

December 14, 2021
Read More
PUBLICATION

Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake

November 4, 2021
Read More
WEBINAR

Molecular Biomarkers and Disease Markers at PsychoGenics [WEBINAR]

October 27, 2021
Read More
PRESS RELEASES

PsychoGenics Chief Innovation Officer Honored for Scientific Excellence

October 11, 2021
Read More
WEBINAR

Preclinical Seizure and Epilepsy [WEBINAR]

July 2, 2021
Read More